Accessibility Menu

Johnson & Johnson(FRA) JNJ

Market Cap€553.19BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1998)+1,348%
5 Year+57%
1 Year+52%
1 Month+2%
€229.85
+1.12%
+2.55Today
Johnson & Johnson last closing stock price
MetricPriceDate
Last closeEUR 229.102026-08-31
Johnson & Johnson stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.12%EUR 231.702026-08-24
1 month+2.23%EUR 224.102026-07-31
3 month+19.19%EUR 192.222026-06-02
Year to date+29.65%EUR 176.702025-12-30
1 year+52.1%EUR 150.622025-08-29
3 year+53.76%EUR 149.002023-09-01
5 year+57.24%EUR 145.702021-09-01
Since inception+1,348.23%EUR 15.701998-06-08

Johnson & Johnson Financials at a Glance

Market Cap

€553.19BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€83.98K

Net Income (TTM)

€18.04K

EPS (TTM)

€7.40

P/E Ratio

31.03

Dividend

€4.53

Beta (Volatility)

-0.05 (Low)

Price

€229.85

Volume

0

Open

€230.95

Previous Close

€229.85

Daily Range

€228.70 - €230.95

52-Week Range

€148.00 - €241.50

Estimated Earnings Date

N/A

JNJ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The MedTech segment offers products used in the interventional solutions. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Industry

Pharmaceuticals

Sector

Health Care

Employees

140,800

CEO

Joaquin Duato, MBA

Website

www.jnj.com

JNJ Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

25.56%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

3.22%

Dividend Yield

1.97%

Payout Ratio

N/A

Stock Overview

Market Cap

€553.19BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.41B

Volume

0

Avg. Volume

408.985

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Johnson & Johnson Performance Analysis

Johnson & Johnson annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 76,178,835,900-4.0%
20232023-12-31EUR 78,763,084,8773.4%
20242024-12-31EUR 82,111,268,3834.3%
20252025-12-31EUR 83,448,378,5111.6%
Johnson & Johnson annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 6.41-3.0%
20232023-12-31EUR 5.12-20.1%
20242024-12-31EUR 5.354.6%
20252025-12-31EUR 9.7882.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€21.77K

+1.0%

Gross Profit

€14.97K

+1.0%

Gross Margin

68.73%

+1.0%

Market Cap

€553.19BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€3.80

N/A

Employees

140,800

N/A

Net Income

€4.76K

+1.0%

EBITDA

€8.02K

+1.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€60.75K

+2.8%

Total Debt

€42.89K

+1.0%

Accounts Receivable

€16.66K

+1.1%

Inventory

€13.25K

+1.2%

Long Term Debt

€32.66K

+1.0%

Short Term Debt

€10.23K

+1.0%

Return on Assets

10.59%

+0.8%

Return on Invested Capital

17.01%

+1.1%

Free Cash Flow

€6.28K

+2.8%

Operating Cash Flow

€7.42K

+2.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About JNJ

What is the current price of Johnson & Johnson?

Johnson & Johnson is trading at €229.85 per share.

What is the 52-week range for Johnson & Johnson?

Over the past 52 weeks, Johnson & Johnson has traded between €148.00 and €241.50.

How much debt does Johnson & Johnson have?

As of the most recent reporting period, Johnson & Johnson reported total debt of €42.89B.

How much cash does Johnson & Johnson have on hand?

Johnson & Johnson reported €17.86B in cash and cash equivalents in its most recent financial results.

What is Johnson & Johnson’s dividend yield?

Johnson & Johnson currently has a dividend yield of 1.97%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services